Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Hueber, Wolfgang; E. Sands, Bruce; Lewitzky, Steve; Vandemeulebroecke, Marc; Reinisch, Walter; Higgins, Peter; Wehkamp, Jan; G. Feagan, Brian; Yao, Michael; Karczewski, Marek; Karczewski, Jacek; Pezous, Nicole; Bek, Stephan; Bruin, Gerard; Mellgard, Bjoern; Berger, C; Londei, Marco; P. Bertolino, Arthur; Tougas, Gervais; Travis, Simon; the Secukinumab in Crohn's Disease Study Group, for

doi:10.1136/gutjnl-2011-301668

Public

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Published in Gut • May 17, 2012

Authors:

Wolfgang Hueber

Bruce E. Sands

Steve Lewitzky

Abstract

OBJECTIVE: The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the treatment of active Crohn's disease. DESIGN: In a double-blind, randomised, placebo-controlled proof-of-concept study, 59 patients with moderate to severe Crohn's diseas...

Subject

Secukinumab

Placebo

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!